US Corporate Distress Financial Stress SEC Filings — May 19, 2026

19-05-2026

Eagle Materials reported record annual revenue of $2.3 billion for fiscal 2026, up 2% year-over-year, driven by strong performance in Heavy Materials (Cement volume +8%, Aggregates volume +24%). However, net earnings declined 9% to $423.8 million and Adjusted EBITDA fell 5% to $774.5 million, reflecting lower Gypsum Wallboard sales volume and prices in the Light Materials sector. The company returned $414 million to shareholders via buybacks and dividends while maintaining a net leverage ratio of 1.9x.

• · Gross profit margin for fiscal 2026 was 28.3%.
• · Cement average annual net sales price decreased 1% to $155.18 per ton in fiscal 2026.
• · Gypsum Wallboard average net sales price for Q4 fiscal 2026 was $213.27 per MSF, down 8% YoY and sequentially down approximately $12 per MSF, with $2 of that due to higher freight costs.
• · Recycled Paperboard average net sales price for Q4 fiscal 2026 was $587.33 per ton, down 1% YoY.
• · Corporate G&A expenses increased 21% in fiscal 2026 due to $4.8 million in technology upgrade costs and $7.8 million in compensation-related costs.
• · Concrete and Aggregates reported a Q4 operating loss of $2.6 million, compared with a loss of $9.4 million in the prior-year Q4 (which included $1.9 million of acquisition-related expenses).
• · The Mountain Cement plant modernization is approximately 60% complete, with commissioning of the new kiln line expected in late calendar 2026.
• · Construction on the Duke, Oklahoma wallboard plant modernization started in fall 2025, with commissioning expected in the second half of calendar 2027.
• · Net leverage ratio (net debt to Adjusted EBITDA) was 1.9x at year-end.
• · Hazard observation reporting improved by 24% in fiscal 2026.

19-05-2026

Healthcare Realty Trust Inc (HR) entered into a $400 million senior unsecured delayed draw term loan agreement on May 15, 2026, with Wells Fargo as administrative agent and a syndicate of lenders. The facility provides additional liquidity for general corporate purposes, including potential acquisitions. The interest rate is tied to the company's debt ratings, with pricing ranging from SOFR+0.675% (strongest rating) to SOFR+1.550% (weakest rating), and the company must maintain at least two debt ratings.

• · The loan is a delayed draw facility, meaning the borrower can draw funds up to the $400M commitment on specified terms and conditions.
• · Interest rate pricing is determined by the company's debt ratings from at least two rating services, with a fallback to Pricing Level 7 if fewer than two ratings are available.
• · The agreement includes standard representations, warranties, covenants, and events of default typical for an unsecured term loan facility.
• · The facility is unsecured and senior in right of payment.
• · The agreement was filed as an exhibit to an 8-K on May 19, 2026, with the agreement dated May 15, 2026.

19-05-2026

Blackstone Mortgage Trust, Inc. (BXMT) completed a $450M offering of 6.250% Senior Secured Notes due 2031 on May 19, 2026. The notes are secured on a first-priority basis by substantially all assets of the company and its guarantors, and proceeds will be used for general corporate purposes including paying down existing secured debt. The issuance increases the company's leverage and interest expense, but provides liquidity for refinancing.

• · The notes were issued in a private offering under Rule 144A and Regulation S.
• · Interest is payable semi-annually on June 1 and December 1, commencing December 1, 2026.
• · The notes mature on June 1, 2031.
• · Optional redemption before March 1, 2031 requires a make-whole premium; on or after that date, redemption is at par plus accrued interest.
• · Up to 40% of the notes can be redeemed before December 1, 2027 using proceeds from certain equity offerings at a price of 106.250%.
• · A change of control triggering event requires the company to offer to repurchase notes at 101% of principal plus accrued interest.
• · The notes are senior secured obligations ranking pari passu with existing First Lien Obligations, including the Term Loan Credit Agreement and the 3.750% and 7.750% Senior Secured Notes.
• · The notes are secured by substantially all assets of the company and guarantors on a first-priority basis, subject to a first lien intercreditor agreement dated October 5, 2021.
• · Upon a Collateral Fall-Away Event, the notes become unsecured.
• · Covenants include a maximum Total Debt to Total Assets Ratio of 83.333% before a Collateral Fall-Away Event and a minimum Total Unencumbered Assets to Total Unsecured Indebtedness Ratio of 1.20 to 1.00 after.
• · The indenture includes events of default that could accelerate repayment of all outstanding notes.

19-05-2026

Innovative Industrial Properties Inc. (IIPR-PA) subsidiary IIP-MA 7 LLC entered into a loan agreement with Amalgamated Bank on May 18, 2026. The loan is secured by a property leased to Curaleaf Massachusetts, Inc. under a lease dated September 1, 2022. The agreement includes standard financial covenants, a Debt Service Coverage Ratio (DSCR) threshold, and provisions for reserve funds, but no specific loan amount or interest rate is disclosed in the filing.

• · The loan is secured by a property leased to Curaleaf Massachusetts, Inc. under a lease dated September 1, 2022, as amended February 6, 2025.
• · The agreement includes a Debt Service Coverage Ratio (DSCR) threshold and provisions for a DSCR Reserve Account if the ratio falls below the threshold.
• · Data Delivery Failure fees escalate from $5,000 (first failure) to $7,500 (second failure) to a 0.25% interest rate increase for subsequent failures.
• · The Default Rate is the lesser of the Maximum Legal Rate and 18% per annum.
• · The loan includes a Static Debt Service Reserve fund requirement.

19-05-2026

InMed Pharmaceuticals entered into an amending agreement with Armistice Capital Master Fund Ltd. to reduce the exercise price of outstanding preferred investment options from $16.60 to $0.80 per common share, covering up to 278,761 common shares. The amendment significantly lowers the conversion threshold for Armistice, potentially leading to future dilution for existing shareholders, but no assurance is a necessary step to maintain financing flexibility given the company's current stock price.

• · The original exercise price was $16.60 per share, set in October 2023.
• · The amended exercise price is $0.80 per share, a 95.2% reduction.
• · The options were issued in a private placement under Section 4(a)(2) of the Securities Act and Regulation D.
• · No assurance is given that any of the options will be exercised.
• · InMed's pipeline includes programs for Alzheimer's, ocular, and dermatological indications.

19-05-2026

TechPrecision Corp (TPCS) subsidiary Ranor Inc. and affiliates entered into a Fourteenth Amendment with Beacon Bank & Trust, extending the maturity date of their $4.5M revolving credit facility from May 15, 2026 to September 15, 2026. The amendment adds covenants requiring the Borrowers to provide a refinancing term sheet by July 31, 2026, and imposes a $15,000 failure-to-perform fee if amounts remain outstanding after the new maturity date. This short-term extension signals potential liquidity pressure, as the company must secure refinancing within four months or face additional costs and potential default.

• · The amendment is the Fourteenth Amendment to the Amended and Restated Loan Agreement and Tenth Amendment to the Second Amended and Restated Promissory Note.
• · If the Borrowers fail to provide a refinancing term sheet by July 31, 2026, Beacon may conduct field examinations of all assets and appraisals of all collateral at all locations.
• · The Borrowers must cooperate with and pay for a lender-ordered appraisal of one of the Company’s properties.
• · Nonpayment of any outstanding amounts after September 15, 2026 constitutes an event of default.
• · There is no material relationship between the Borrowers and Beacon other than the loan agreements and past borrowing relationship.

19-05-2026

Nexalin Technology, Inc. (NXL) announced the closing of its acquisition of PONM, Inc., the digital health platform behind its HALO™ Clarity and Nexalin NeuroCare™ programs, from GreenLight Ventures, LLC. Total consideration is $1.3 million payable in Nexalin common stock tranches tied to market performance. The acquisition gives Nexalin control over AI-integrated remote patient monitoring, clinical data capture, and virtual-care infrastructure already deployed at UCSD, and is expected to support the planned 160-participant FDA pivotal trial for HALO™ Clarity in moderate-to-severe insomnia, with enrollment expected to begin in Q2 2026. However, the transaction involves no upfront cash and the consideration is entirely stock-based, which may dilute existing shareholders, and the company faces significant regulatory and commercialization risks.

• · GreenLight Ventures has become a meaningful equity holder in Nexalin as part of the transaction.
• · Nexalin and GreenLight entered into a strategic partnership providing continued access to product, engineering, quality assurance, cybersecurity, regulatory, behavioral-health, and commercial-development capabilities.
• · The PONM platform is already deployed at UCSD supporting phases one through five of the Nexalin NeuroCare™ virtual clinic for the TBI/PTSD military study.
• · The Nexalin Gen-2 SYNC 15 milliamp neurostimulation device has been approved in China, Brazil, Oman, and Israel.
• · The acquisition consideration is payable in shares of Nexalin common stock issued in tranches over time at prices tied to Nexalin’s market performance.

19-05-2026

Bitcoin Depot Inc. received a Nasdaq delisting notice on May 18, 2026, following its Chapter 11 bankruptcy filing on May 17, 2026, and failure to timely file its Form 10-Q for the period ended March 31, 2026. Trading of the company's Class A common stock and warrants will be suspended at the opening of business on May 26, 2026, and a Form 25-NSE will be filed to remove the securities from listing and registration. The company does not intend to appeal Nasdaq's determination, and it cautions that holders of its securities could experience a significant or complete loss on their investment.

• · The delisting is based on Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1 due to the Chapter 11 filing, and also on failure to timely file Form 10-Q for the period ended March 31, 2026 (Nasdaq Listing Rule 5250(c)).
• · The company's warrants have an exercise price of $80.50 per share.
• · The company is an emerging growth company and has not elected to use the extended transition period for complying with new or revised financial accounting standards.

19-05-2026

Blackstone Digital Infrastructure Trust Inc. filed an 8-K on May 19, 2026, announcing the amendment and restatement of its charter, effective upon formation on November 21, 2025. The charter establishes a seven-member board, includes provisions for director removal requiring Blackstone consent while the management agreement is in effect, and renounces corporate opportunities for Blackstone and non-employee directors. The filing also confirms the company's intent to qualify as a REIT and details indemnification and expense advancement for directors and officers.

• · The corporation was formed on November 21, 2025, under Maryland law.
• · The principal office in Maryland is c/o CSC-Lawyers Incorporating Service Company, 7 St. Paul Street, Suite 820, Baltimore, MD 21202.
• · The board may fill vacancies by majority vote of remaining directors, even if less than a quorum.
• · Stockholders have no preemptive or appraisal rights unless the board determines otherwise.
• · The board may revoke the REIT election if deemed no longer in the corporation's best interests.
• · Director removal requires a majority stockholder vote and, while the Management Agreement is in effect, Blackstone consent for Blackstone designees.
• · The corporation renounces any interest in business opportunities presented to non-employee directors or Blackstone affiliates, unless expressly offered to a director in that capacity.

19-05-2026

MSP Recovery, Inc. reported fiscal 2025 fourth quarter and full year financial results with revenue of $67.3 million for the full year 2025, compared to $66.0 million in 2024, representing 2% growth. However, net loss attributable to common stockholders widened significantly to $457.8 million for the full year 2025 from $209.3 million in 2024. For Q4 2025, revenue was $16.0 million compared to $15.5 million in Q4 2024, with a net loss of $163.0 million versus $79.8 million in the prior year quarter. Despite the revenue increase, operating expenses rose substantially, and the company recognized a $19.6 million goodwill impairment charge during the year.

• · Goodwill impairment charge of $19.6 million was recognized during fiscal 2025.
• · Total operating expenses increased significantly, contributing to the widened net loss.
• · The company's revenues grew only 2% year-over-year, indicating minimal top-line expansion despite larger net losses.
• · Q4 2025 net loss more than doubled compared to Q4 2024, from $79.8 million to $163.0 million.

19-05-2026

Sabre Corporation announced the issuance of $150.0 million of 7.00% Exchangeable Senior Notes due 2031 by its wholly-owned subsidiary Sabre GLBL Inc., with the proceeds intended to repurchase $100.0 million of existing 7.32% exchangeable notes due 2026 at par plus accrued interest, and to retire the remaining outstanding notes over time, resulting in no incremental indebtedness. The initial exchange price of approximately $2.24 per share represents a 30% premium over the May 13, 2026 closing price of $1.72. While the refinancing extends debt maturities and avoids new net debt, the high 7.00% coupon and potential dilution from exchange into common stock (initial exchange rate of 447.2272 shares per $1,000 principal) represent increased interest cost and shareholder dilution risk.

• · The new notes are senior, unsecured obligations of Sabre GLBL, fully and unconditionally guaranteed by Sabre and Sabre Holdings.
• · Interest on the new notes is payable semi-annually on May 15 and November 15, beginning November 15, 2026.
• · Notes mature on May 15, 2031, unless earlier repurchased, redeemed or exchanged.
• · Before November 15, 2030, noteholders may exchange only upon certain events; after that date, exchange is at any time until the second scheduled trading day before maturity.
• · Sabre GLBL may elect to settle exchanges in cash, common stock, or a combination.
• · Sabre GLBL may redeem the notes for cash on or after May 21, 2029, if the stock price is at least 130% of the exchange price for a specified period.
• · Holders may require repurchase on May 15, 2029, at 100% of principal plus accrued interest.
• · A 'Fundamental Change' triggers a holder put option at 100% of principal plus accrued interest.
• · Initial holders may sell common stock or enter derivative positions to hedge, potentially decreasing the market price of common stock or the notes.
• · The new notes and any shares deliverable upon exchange are not registered under the Securities Act and are offered only to qualified institutional buyers and institutional accredited investors.

19-05-2026

Southwest Airlines entered into an Increase Joinder Agreement on May 19, 2026, amending its existing Term Loan Credit Agreement to add $1.0 billion in incremental term loans, bringing total outstanding term loan principal to $1.5 billion. The loans mature on March 11, 2029, and are secured by aircraft and related assets. The company's existing revolving credit facility was not amended.

• · The Increase Joinder also amends the uncommitted incremental term loan feature to allow up to $1.0 billion in additional incremental term loan commitments after the effective date.
• · The Term Loans mature on March 11, 2029, and may be prepaid at any time without premium or penalty upon three business days' notice.
• · Amounts prepaid under the Amended Credit Agreement may not be reborrowed.
• · The Term Loans are secured by a security interest in certain aircraft and related assets, with a minimum collateral coverage ratio requirement.
• · The company's existing revolving credit facility was not amended in connection with this transaction.

19-05-2026

GoPro has retained Houlihan Lokey as its financial advisor to evaluate a potential sale and other strategic alternatives, following unsolicited inbound inquiries from parties in defense, consumer, and financial sectors. The company has not set a timetable for the process and has not made any decisions regarding a transaction. There are no assurances as to the outcome or timing of any potential deal.

• · The engagement follows GoPro's May 11 announcement of unsolicited inbound strategic inquiries from parties across defense, consumer, and financial sectors.
• · Houlihan Lokey is a global investment bank with strong ties into defense and consumer sectors.
• · Fenwick & West is acting as legal advisor to GoPro.
• · GoPro has been recognized as an employer of choice by Outside Magazine and U.S. News & World Report.
• · Forward-looking statements include risks that the strategic review may not result in a transaction or increase shareholder value.

19-05-2026

Humana Inc. completed the issuance and sale of $750 million each of Pre-Capitalized Trust Securities (P-Caps) through two trusts (2036 Trust and 2055 Trust) on May 15, 2026, providing on-demand capital and liquidity. The P-Caps allow Humana to issue up to $750 million of 6.062% Senior Notes due 2036 and $750 million of 6.887% Senior Notes due 2055 over ten- and thirty-year periods, respectively. The trusts invested proceeds in U.S. Treasury strips, and Humana will pay semi-annual facility fees of 1.661% and 1.916% on unexercised portions, with mandatory redemption of P-Caps in 2036 and 2055.

• · The P-Caps were sold to initial purchasers for resale to qualified institutional buyers under Rule 144A and can only be held by qualified purchasers under Section 3(c)(7) of the Investment Company Act.
• · The P-Caps do not carry registration rights.
• · Upon a change of control triggering event, the Company must offer to repurchase Senior Notes at 101% of principal amount plus accrued interest.
• · The Company may redeem Senior Notes before the Par Call Date at the greater of principal amount and a make-whole redemption price; on or after the Par Call Date at 100% of principal amount.
• · The Indentures include covenants restricting liens, mergers, and asset sales.
• · The 2036 Senior Notes mature on February 15, 2036; the 2055 Senior Notes mature on November 15, 2055.
• · The P-Caps are mandatorily redeemable on February 15, 2036 (2036 Trust) and November 15, 2055 (2055 Trust).

19-05-2026

HF Sinclair Corporation (DINO) entered into a Stock Purchase Agreement on May 18, 2026 to repurchase 1,455,180 shares of its common stock from REH Advisors Inc. at $68.72 per share for an aggregate purchase price of $100 million, funded with cash on hand. This is the twenty-first such privately negotiated transaction with REH and brings total repurchases under the company's $1 billion share repurchase program to $717 million. The transaction is expected to close on or around May 21, 2026, but the program may be discontinued at any time by the Board.

• · The repurchase price per share is $68.72, representing a premium/discount to market price (not specified).
• · The shares repurchased will be held as treasury stock.
• · The repurchase is the twenty-first privately negotiated transaction between the company and REH Advisors Inc.
• · The program may be discontinued at any time by the Board of Directors.
• · Future repurchases depend on market conditions, corporate, tax, regulatory and other considerations.

19-05-2026

Transocean Ltd. entered into a support agreement with Famatown Finance Limited and Kristian Johansen on May 19, 2026, agreeing to nominate Mr. Johansen to its board of directors, contingent on shareholder approval and the consummation of Transocean's acquisition of Valaris Limited. The agreement includes nomination and observer rights, standstill and voting covenants, and termination conditions if the Famatown Parties' ownership falls below 3.5% of Transocean's outstanding shares. The filing also notes that a joint preliminary proxy statement for the Valaris acquisition was filed with the SEC on the same date.

• · The Famatown Support Agreement includes a Re-Nomination Period of two years from the extraordinary general meeting, extendable if Mr. Johansen or a Replacement Director is elected at subsequent meetings.
• · If Mr. Johansen is not elected, Famatown Parties can nominate a Replacement Director, and Transocean Board must promptly nominate that individual.
• · The agreement terminates if Famatown Parties breach standstill/voting commitments or if Mr. Johansen fails to comply with Transocean policies.
• · The joint preliminary proxy statement for the Valaris acquisition was filed on May 19, 2026, and is not yet final.

19-05-2026

Jaguar Health, Inc. entered into an Exchange Agreement with Uptown Capital, LLC to partition a $12.5 million Royalty Repayment Amount into a new Partitioned Royalty and exchange it for 500 shares of Series Q Convertible Preferred Stock. The exchange is structured as a Section 3(a)(9) exchange with no additional cash consideration, and the outstanding balance of the original Royalty Interest will be reduced by $12.5 million. The transaction reduces Jaguar Health's debt-like royalty obligation by $12.5 million in exchange for equity dilution, but no new cash is raised and no other financial metrics are disclosed.

• · The exchange is intended to comply with Section 3(a)(9) of the Securities Act of 1933, meaning no new registration is required.
• · The holding period for the Exchange Shares under Rule 144 will tack back to the original Royalty Interest holding period starting December 22, 2020.
• · Uptown Capital represents it will not beneficially own more than 9.99% of Jaguar Health's outstanding common stock following the exchange.
• · No Event of Default has occurred under the Royalty Interest, and any prior defaults are not waived by this agreement.
• · The Exchange Shares are issued in book-entry form and are fully paid and non-assessable.

19-05-2026

Bank First Corporation (BFC) announced a definitive agreement to acquire PSB Holdings, Inc. (Peoples) in an all-stock transaction valued at approximately $202.9 million. The combined entity will have over $7.6 billion in assets, expanding Bank First's footprint into North Central Wisconsin and the greater Milwaukee area. The deal is expected to close in Q4 2026, subject to regulatory and shareholder approvals.

• · Exchange ratio: 0.3470 Bank First shares per Peoples share.
• · Bank First's stock closing price on May 18, 2026: $143.66 per share.
• · Peoples had $1.50B in assets, $1.12B in net loans, $1.19B in deposits, and $133.87M in equity as of March 31, 2026.
• · Combined company will have $7.6B in assets, $5.64B in loans, and $6.27B in deposits.
• · Bank First's recent acquisition of Centre 1 Bancorp closed on January 1, 2026.
• · Transaction expected to close in Q4 2026.

19-05-2026

GeoVax Labs, Inc. announced a $3 million private placement financing priced at-the-market under Nasdaq rules, with gross proceeds of approximately $3 million from the sale of 2,027,027 shares of common stock (or equivalents) and accompanying Series A and Series B warrants. The company plans to use net proceeds for working capital and general corporate purposes, while its priority program GEO-MVA is advancing toward a pivotal Phase 3 clinical trial in the second half of 2026. However, the financing is dilutive to existing shareholders, and the company remains a clinical-stage biotech with no approved products, facing significant development and regulatory risks.

• · The offering is expected to close on or about May 19, 2026.
• · The securities are being sold in reliance on an exemption under Section 4(a)(2) of the Securities Act and/or Regulation D.
• · GeoVax has agreed to file a registration statement with the SEC covering the resale of the shares and underlying shares.
• · GeoVax's priority program GEO-MVA is advancing under an expedited regulatory pathway with plans for a pivotal Phase 3 trial in H2 2026.
• · Gedeptin has completed a Phase 1/2 trial in advanced head and neck cancer and is being advanced into combination strategies.
• · GEO-CM04S1 is a next-generation COVID-19 vaccine candidate being evaluated in immunocompromised populations.

19-05-2026

Aether Holdings, Inc. entered into a Note Purchase Agreement with Streeterville Capital, LLC on May 13, 2026, issuing a secured promissory note with an initial principal amount of $3,240,000. The note carries an original issue discount of $240,000 and transaction expenses of $30,000, resulting in net proceeds of $3,000,000 to the company. The note is secured by all company assets, intellectual property, and subsidiary guarantees. The agreement includes restrictive covenants limiting additional debt and equity issuances without investor consent.

• · The note is secured by all company assets, intellectual property, and subsidiary guarantees.
• · Company covenants include timely SEC filings, maintaining listing on NYSE/NYSE American/Nasdaq, and no restricted issuances without investor consent.
• · Restricted issuances include variable rate transactions, convertible securities with market-price-based conversion, and certain anti-dilution provisions.
• · The agreement contains representations regarding company's SEC filings, absence of undisclosed financing, and non-shell company status.

19-05-2026

Rithm Property Trust Inc. (RPT-PC) entered into a Flow Mortgage Loan Purchase and Sale Agreement on May 13, 2026, to purchase a portfolio of multifamily residential transition loans (RTLs) originated by Genesis Capital LLC, a subsidiary of Rithm Capital Corp. The agreement allows for periodic purchases of RTLs on a servicing-released basis, with Genesis serving as servicer. No financial terms or amounts were disclosed in the filing.

• · The Flow MLPA contains customary terms including representations and warranties and the Seller's repurchase obligation for non-conforming loans.
• · The Company's obligation to purchase loans is subject to conditions precedent, including delivery of specified loan documentation.
• · The full text of the Flow MLPA will be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ending June 30, 2026.

19-05-2026

Rapid Micro Biosystems, Inc. entered into an underwriting agreement on May 18, 2026, for a public offering of 3,581,000 shares of Class A common stock and accompanying Series A and Series B warrants, along with pre-funded warrants for up to 1,463,000 shares, at a combined offering price of $1.955 per unit. The company also conducted a concurrent registered direct offering to directors and officers for 71,607 shares and warrants, raising gross proceeds of approximately $140,000. Net proceeds from the public offering are estimated at $8.9 million, which will be used for working capital and general corporate purposes.

• · The public offering is expected to close on May 20, 2026.
• · Series A Common Stock Warrants have an exercise price of $1.955 per share, are exercisable 6 months from issuance, and expire one year from issuance.
• · Series B Common Stock Warrants have an exercise price of $2.340 per share, are exercisable 6 months from issuance, and expire five years from issuance.
• · Pre-Funded Warrants have an exercise price of $0.01 per share and are exercisable immediately until fully exercised.
• · The concurrent offering is contingent upon the closing of the public offering.
• · The securities were issued under a shelf registration statement on Form S-3 (File No. 333-276081) declared effective on December 26, 2023.

19-05-2026

Energy Transition Special Opportunities (ticker ETSS U) priced its $150 million initial public offering of 15,000,000 units at $10.00 per unit on May 14, 2026, with the units expected to begin trading on the NYSE on May 15, 2026. The blank check company intends to target businesses in climate transition, specialty finance, renewable energy, and regenerative agriculture. The offering is expected to close on May 18, 2026, subject to customary conditions, and the underwriters have a 45-day option to purchase up to an additional 2,250,000 units to cover over-allotments.

• · The Company is a blank check company formed to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination.
• · Target sectors include climate transition, specialty finance, renewable energy, and regenerative agriculture.
• · The registration statement was declared effective by the SEC on May 14, 2026.
• · The underwriters have a 45-day option to purchase up to an additional 2,250,000 units at the IPO price to cover over-allotments.
• · Once separate trading begins, Class A ordinary shares will trade under 'ETSS' and warrants under 'ETSS WS' on the NYSE.

19-05-2026

Hancock Whitney Corporation (Parent) has entered into a definitive Agreement and Plan of Merger to acquire OFB Bancshares, Inc. (Company) through a two-step merger process: first, its wholly-owned subsidiary Citrus Acquisition Corp. will merge into OFB Bancshares, and then the surviving entity will merge into Hancock Whitney. The transaction, dated May 15, 2026, is subject to regulatory approvals, shareholder approval, and other customary conditions. No financial terms (e.g., consideration per share, total deal value) are disclosed in this filing.

• · The merger structure involves a first step merger under Florida and Delaware law, followed by an upstream merger under Mississippi and Florida law.
• · Concurrently with the agreement, directors and certain shareholders of OFB Bancshares entered into voting and support agreements (Exhibit B) to vote in favor of the transaction.
• · The Company Board has resolved to recommend the merger to its shareholders.
• · The agreement includes customary representations, warranties, covenants, and conditions precedent, including regulatory approvals and absence of a Material Adverse Effect.
• · The filing does not disclose the merger consideration, termination fees, or any specific financial metrics.

19-05-2026

Zoomcar Holdings, Inc. entered into a letter agreement with ACM Zoomcar Convert LLC to resolve outstanding judgments totaling approximately $6 million. Zoomcar will pay $2.5 million in cash by October 31, 2026, and the remaining ~$3.5 million plus interest will be converted into equity at the terms of a future financing. ACM also receives at least 10% of gross proceeds from any capital raises and grants a courtesy standstill until March 31, 2027, while Zoomcar withdraws appeals and provides asset lists. The agreement resolves legal uncertainty but dilutes existing shareholders.

• · Zoomcar must provide ACM with a list of all assets and bank accounts, updated from time to time.
• · ACM may terminate the Courtesy Standstill Period early if it believes Zoomcar is not working to pay.
• · Zoomcar withdraws all appeals of ACM's judgment and submits a confession of judgment.

19-05-2026

STORE Capital closed a $567.0 million securitization (Series 2026-1) under its Master Funding program, issuing four classes of fixed-rate notes with a weighted average interest rate of 5.28% and a weighted average life of 6.32 years. The transaction was significantly oversubscribed, allowing a more than 60% upsize, and net proceeds were used to redeem $520.3 million of higher-cost existing notes (6.44% coupon) and to fund growth. While the refinancing creates substantial interest savings, the new issuance carries a higher weighted average rate than the prior AAA-rated tranches (5.22%-5.31% vs. the redeemed 6.44%), and the company's reliance on private placements and Rule 144A limits liquidity.

• · The notes were issued in a private placement under Rule 144A and are not registered under the Securities Act.
• · The weighted average life of the new notes is 6.32 years.
• · The redeemed notes had a May 2028 maturity date.
• · STORE Capital owns more than 3,500 property locations across the U.S., substantially all profit centers.

19-05-2026

Capital Southwest Corporation (CSWC) entered into Sixth Amendments to its equity distribution agreements on May 19, 2026, increasing the maximum aggregate offering amount under its at-the-market (ATM) program from $1.0 billion to $2.0 billion. After giving effect to the amendments, approximately $1.1 billion in shares remain available for sale. The amendments were entered into with Jefferies LLC, Raymond James & Associates, Inc., Citizens JMP Securities, LLC, and B. Riley Securities, Inc.

• · The Sixth Amendments were entered into on May 19, 2026, and amend the Third Amended and Restated Equity Distribution Agreements (dated May 26, 2021) with Jefferies and Raymond James, and the Amended and Restated Equity Distribution Agreements (also dated May 26, 2021) with Citizens JMP Securities and B. Riley.
• · The Equity Distribution Agreements had been previously amended on August 3, 2021, November 2, 2021, August 2, 2022, May 21, 2024, and October 30, 2024.
• · The shares will be issued pursuant to the Company's shelf registration statement on Form N-2 (File No. 333-282873) and the Prospectus, as supplemented.
• · The opinion of Eversheds Sutherland (US) LLP relating to the legality of the issuance and sale of the shares is attached as Exhibit 5.1.

19-05-2026

Patterson-UTI Energy completed a $500 million offering of 6.050% Senior Notes due 2036. The company intends to use the net proceeds to redeem its outstanding 3.95% Senior Notes due 2028 and for general corporate purposes. The new notes bear a significantly higher coupon (6.050% vs. 3.95%), increasing interest expense, but extend the maturity profile to 2036.

• · The Notes are senior unsecured obligations ranking equally with existing and future senior unsecured debt.
• · The Notes are effectively subordinated to any future secured debt and structurally subordinated to subsidiary liabilities.
• · No subsidiaries are currently required to guarantee the Notes; any future guarantees would rank equally with the guarantors' unsecured senior debt.
• · The company may redeem the Notes at its option prior to February 15, 2036 at a specified redemption price, and at 100% of principal thereafter.
• · Interest on the Notes is payable semi-annually on May 15 and November 15.
• · The Notes were issued under a base indenture dated November 15, 2019, supplemented by a third supplemental indenture dated May 19, 2026.

19-05-2026

Sunshine Biopharma Inc. announced the pricing of a $6.0 million public offering of 12,000,000 Common Units (or Pre-Funded Units) at $0.50 per unit, with each unit including one share (or Pre-Funded Warrant) and two Series C Warrants. The offering is expected to close on May 19, 2026, with net proceeds used for general corporate purposes and working capital. The company markets 60 generic drugs in Canada and has two proprietary drug programs in development.

• · The offering consists of 12,000,000 Common Units (or Pre-Funded Units), each with one share (or Pre-Funded Warrant) and two Series C Warrants.
• · Series C Warrants have an initial exercise price of $0.50 and expire five years after issuance.
• · Pre-Funded Warrants are exercisable immediately at $0.00001 per share.
• · Aegis Capital Corp. is the exclusive placement agent.
• · Registration statement on Form S-1 (No. 333-295800) was declared effective on May 18, 2026.
• · The company markets 60 generic prescription drugs in Canada with 12 additional launches planned for 2026.
• · Proprietary drug programs: K1.1 mRNA (liver cancer) and PLpro protease inhibitor (SARS-related coronaviruses).

19-05-2026

AIM ImmunoTech reported a significant increase in stockholder equity from a deficit of approximately $9.8 million as of December 31, 2025, to positive equity of approximately $2.1 million as of March 31, 2026, an improvement of about $11.9 million. The company also extended the maturity date of its promissory note with Streeterville Capital, LLC to June 30, 2027, with an outstanding balance of approximately $1.68 million. While the equity improvement and note extension enhance financial flexibility, the company still has a relatively small equity base and a material debt obligation, and its clinical programs remain subject to significant risks and uncertainties.

• · The promissory note was originally issued on February 16, 2024.
• · The company has raised additional equity-generating funds through various transactions since March 31, 2026.
• · The company's lead product is Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator.
• · The company is focused on the treatment of late-stage pancreatic cancer.

19-05-2026

On May 13, 2026, Diversified Energy Company's indirect subsidiary DP Red River LLC issued $850 million in asset-backed securities (ABS XII Notes) to refinance existing debt and for general corporate purposes. The offering included $590 million of 6.016% Class A-1 Notes and $260 million of 6.910% Class A-2 Notes, both due 2046, with an anticipated repayment date in May 2031. Proceeds were used to redeem higher-coupon existing notes (including 8.121% and 8.946% series), reducing interest costs, but the new notes carry significant covenants and accelerated amortization triggers tied to production and coverage ratios.

• · The ABS XII Notes are secured by upstream producing assets in the Western Anadarko Basin (Texas and Oklahoma), which previously served as collateral for the redeemed Existing Notes.
• · The notes have an anticipated repayment date of May 2031 and a legal final maturity of May 2046, with monthly principal and interest payments.
• · Covenants include maintaining a specified reserve account, optional/mandatory prepayment provisions, and accelerated amortization triggers tied to debt service coverage, loan-to-value ratios, production metrics, hedging requirements, and failure to repay by the Anticipated Repayment Date.
• · The coupon increases if the notes are not repaid or refinanced by the Anticipated Repayment Date.
• · The Issuer is a limited-purpose, bankruptcy-remote, wholly-owned indirect subsidiary of Diversified Energy Company.

19-05-2026

Pitney Bowes announced the extension of its Revolving Credit Facility and Term Loan A to May 2031, with the $450 million RCF and $152 million Term Loan A sizes unchanged. Fitch Ratings initiated coverage with a BB- Long-Term Issuer Default Rating and Stable Outlook, assigning 'BB+' to senior secured debt and 'BB-' to senior unsecured bonds. The company highlighted strengthened liquidity and financial flexibility, but no specific financial performance metrics or period-over-period comparisons were provided in the filing.

• · Fitch assigned issue-level ratings of 'BB+' to senior secured debt and 'BB-' to senior unsecured bonds.
• · The company serves more than 90 percent of the Fortune 500.
• · The credit facility amendments provide greater flexibility for strategic capital allocation over a five-year term.

19-05-2026

Kimbell Royalty Partners, LP announced a $147 million acquisition of mineral and royalty interests from Mesa Royalties in the Permian Basin, expected to close in Q2 2026. The deal is funded with 70% newly issued OpCo units and 30% cash, and is expected to be immediately accretive to distributable cash flow per unit. The acquired assets include over 2,300 gross producing wells and over 600 undeveloped locations, with estimated NTM cash flow of $23.3 million.

• · The acquisition is expected to close in Q2 2026 with an effective date of June 1, 2026.
• · Kimbell's oil weighting is expected to increase from 32% to 33% of daily production mix.
• · Over 98% of all rigs in the continental US are located in counties where Kimbell will hold mineral interests post-acquisition.
• · The purchase price per total proved Boe is approximately $19.17.
• · The acquired assets are located across 15 Permian counties, with 70% in Delaware Basin and 30% in Midland Basin.

19-05-2026

Exyn Technologies, Inc. announced the pricing of its initial public offering (IPO) of 2,500,000 units at $7.75 per unit, each consisting of one share of common stock and one warrant, for total gross proceeds of approximately $19.4 million. The shares and warrants are expected to begin trading on the Nasdaq Capital Market on May 15, 2026, under the tickers EXYN and EXYNW. The company intends to use net proceeds for growth capital, working capital, debt repayment, and general corporate purposes, with the offering expected to close on or about May 18, 2026.

• · The underwriter has a 30-day option to purchase up to an additional 375,000 shares of common stock and/or 375,000 warrants.
• · The registration statement on Form S-1 (File No. 333-294453) was declared effective by the SEC on May 14, 2026.
• · Lucid Capital Markets is acting as the sole book-running manager for the offering.
• · The company is a pioneer in multi-platform robotic autonomy for complex, GPS-denied environments.

19-05-2026

iPower Inc. announced the launch of its AI infrastructure strategy, positioning itself as a capital provider for GPU clusters and AI assets. The company will use an existing $30M financing facility (from December 2025) and committed up to $3M to purchase sUSDai, a yield-bearing instrument backed by GPU-collateralized loans. While emphasizing a strong capital position and early-mover advantage, the filing is forward-looking with no current revenue from AI operations, and the balance sheet impact depends on future execution.

• · The existing $30M facility was established in December 2025, not new at the time of this filing.
• · The initial $3M investment is from 'new financing proceeds,' suggesting iPower raised incremental capital or drew down a portion of the facility.
• · The strategy targets strong returns on invested capital (ROIC) through disciplined asset selection.
• · Forward-looking statements highlight risk of inability to successfully deploy capital or generate revenue from the AI strategy.
• · No quantitative targets or prior financial results related to AI infrastructure are provided.

19-05-2026

Ford Credit Floorplan Master Owner Trust A filed an 8-K on May 19, 2026, reporting the entry into material definitive agreements (Series 2026-2 Indenture Supplement and Account Control Agreement) in connection with the issuance of asset-backed securities (Notes) under a Prospectus dated May 5, 2026. The filing does not disclose any financial performance data, so no period-over-period comparisons or quantitative metrics are available.

19-05-2026

Mobix Labs, Inc. amended its senior secured convertible note with Leviston Resources, increasing the principal from $3M to $4M and receiving an additional $833,333 cash advance. The entire $4M principal plus accrued interest was subsequently converted into 2,500,000 shares of Class A Common Stock between May 12-18, 2026, fully satisfying the note. The company also entered an Investor Rights Agreement granting Leviston the option to acquire up to $4.0M in additional secured convertible notes over seven months on similar terms.

• · The Original Note was originally issued on March 31, 2026.
• · Leviston at no time beneficially owned in excess of 4.99% of outstanding Class A Common Stock.
• · The conversion was exempt from registration under Section 3(a)(9) of the Securities Act.
• · The Original Note, Securities Purchase Agreement, and Registration Rights Agreement terminated upon full satisfaction.
• · The Investor Rights Agreement grants Leviston the right to acquire up to $4.0M in additional secured convertible notes on a pari passu basis over seven months.

19-05-2026

HPS Corporate Lending Fund issued $600M in 6.300% notes due 2031, generating net proceeds of approximately $594.3M. The notes are unsecured and rank pari passu with existing unsecured debt, while the fund entered an interest rate swap to convert the fixed-rate liability to floating-rate (3-month Term SOFR + 2.394%) to align with its floating-rate loan portfolio. Proceeds will be used for investments, reducing borrowings, and general corporate purposes.

• · The notes mature on August 19, 2031, with interest payable semi-annually on February 19 and August 19, commencing February 19, 2027.
• · The notes are general unsecured obligations, ranking senior to subordinated debt, pari passu with other unsecured unsubordinated debt, effectively junior to secured debt, and structurally junior to all debt of subsidiaries.
• · The indenture includes covenants requiring compliance with asset coverage requirements under the Investment Company Act of 1940 and to provide financial information if the fund is no longer subject to Exchange Act reporting.
• · Upon a change of control repurchase event, the fund must offer to repurchase the notes at 100% of principal plus accrued interest.
• · The notes were offered under Rule 144A and Regulation S, not registered under the Securities Act.
• · The Registration Rights Agreement obligates the fund to file an exchange offer registration statement or a shelf registration statement, with additional interest payable if registration obligations are not met by specified dates.